First-line bevacizumab (BEV) plus chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.

被引：1
|
作者：
Kahan, Zsuzsanna [1 ]
Petruzelka, Lubos [2 ]
Eniu, Alexandru [3 ]
Anghel, Rodica [4 ]
Koynov, Krassimir [5 ]
Vrbanec, Damir [6 ]
Lang, Istvan [7 ]
Ahlers, Silke [8 ]
Brodowicz, Thomas [9 ,10 ]
Zielinski, Christoph [9 ,10 ]
机构：
[1] Univ Szeged, Szeged, Hungary
[2] Charles Univ Prague, Prague, Czech Republic
[3] Inst Canc Res, Cluj Napoca, Romania
[4] Univ Med & Pharm Bucharest, Bucharest, Romania
[5] Univ Hosp, Sofia, Bulgaria
[6] Univ Hosp Rebro, Zagreb, Croatia
[7] Natl Inst Oncol, Budapest, Hungary
[8] IST GmbH, Mannheim, Germany
[9] Med Univ Vienna, Vienna, Austria
[10] CECOG, Vienna, Austria
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-LB-177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB177
引用
收藏
页数：2
相关论文
共 50 条
  • [41] First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial
    Zhang, L.
    Huang, Y.
    Yang, Y.
    Ma, S.
    Lin, X.
    Lin, L.
    Zhou, T.
    Deng, Y.
    Zhang, C.
    Ding, X.
    Wang, S.
    Wang, R.
    Feng, G.
    Chen, Y.
    Xu, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [42] FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
    Cremolini, Chiara
    Loupakis, Fotios
    Antoniotti, Carlotta
    Lupi, Cristiana
    Sensi, Elisa
    Lonardi, Sara
    Mezi, Silvia
    Tomasello, Gianluca
    Ronzoni, Monica
    Zaniboni, Alberto
    Tonini, Giuseppe
    Carlomagno, Chiara
    Allegrini, Giacomo
    Chiara, Silvana
    D'Amico, Mauro
    Granetto, Cristina
    Cazzaniga, Marina
    Boni, Luca
    Fontanini, Gabriella
    Falcone, Alfredo
    LANCET ONCOLOGY, 2015, 16 (13): : 1306 - 1315
  • [43] Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial
    Saji, Shigehira
    Taira, Naruto
    Kitada, Masahiro
    Takano, Toshimi
    Takada, Masahiro
    Ohtake, Tohru
    Toyama, Tatsuya
    Kikawa, Yuichiro
    Hasegawa, Yoshie
    Fujisawa, Tomomi
    Kashiwaba, Masahiro
    Ishida, Takanori
    Nakamura, Rikiya
    Yamamoto, Yutaka
    Toh, Uhi
    Iwata, Hiroji
    Masuda, Norikazu
    Morita, Satoshi
    Ohno, Shinji
    Toi, Masakazu
    LANCET ONCOLOGY, 2022, 23 (05): : 636 - 649
  • [44] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Alessandra Fabi
    Michelangelo Russillo
    Gianluigi Ferretti
    Giulio Metro
    Cecilia Nisticò
    Paola Papaldo
    Ferdinando De Vita
    Giuliana D’Auria
    Antonello Vidiri
    Diana Giannarelli
    Francesco Cognetti
    BMC Cancer, 12
  • [45] Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy
    Fabi, Alessandra
    Russillo, Michelangelo
    Ferretti, Gianluigi
    Metro, Giulio
    Nistico, Cecilia
    Papaldo, Paola
    De Vita, Ferdinando
    D'Auria, Giuliana
    Vidiri, Antonello
    Giannarelli, Diana
    Cognetti, Francesco
    BMC CANCER, 2012, 12
  • [46] MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC)
    Smith, I. E.
    Biganzoli, L.
    Cortes-Funes, H.
    Franke, F.
    Kamel, Y. Mostafa
    Pierga, J. Y.
    Pritchard, K. I.
    Stroyakovs, D.
    Thomssen, C.
    Vinholes, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 221 - 221
  • [47] FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer
    Bergh, Jonas
    Jonsson, Per-Ebbe
    Lidbrink, Elisabet Kerstin
    Trudeau, Maureen
    Eiermann, Wolfgang
    Brattstrom, Daniel
    Lindemann, Justin P. O.
    Wiklund, Fredrik
    Henriksson, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1919 - 1925
  • [48] Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC)
    Rugo, H. S.
    Campone, M.
    Amadori, D.
    Wardley, A.
    Villa, E.
    Conte, P. F.
    Mudenda, B.
    McHenry, B.
    Pivot, X.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Quality of life (QoL) results from the TURANDOT trial comparing two bevacizumab (BEV)-containing regimens as first-line treatment for HER2-negative metastatic breast cancer (mBC)
    Lang, I.
    Inbar, M. J.
    Kahan, Z.
    Greil, R.
    Beslija, S.
    Stemmer, S. M.
    Kaufman, B.
    Ahlers, S.
    Brodowicz, T.
    Zielinski, C.
    CANCER RESEARCH, 2012, 72
  • [50] Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy inadvanced nonsquamous non-small cell lung cancer (WJOG 5910L): An open-label, randomized, phase II trial.
    Takeda, Masayuki
    Seto, Takashi
    Hayashi, Hidetoshi
    Okada, Morihito
    Azuma, Koichi
    Sugawara, Shunichi
    Daga, Haruko
    Hirashima, Tomonori
    Yonesaka, Kimio
    Urata, Yoshiko
    Murakami, Haruyasu
    Saito, Haruhiro
    Kubo, Akihito
    Sawa, Toshiyuki
    Miyahara, Eiji
    Nogami, Naoyuki
    Yamanaka, Takeharu
    Nakanishi, Yoichi
    Nakagawa, Kazuhiko
    Okamoto, Isamu
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345